Business Overview
PURE Bioscience manufactures and distributes products based on patented stabilized ionic silver (SDC), including PURE Hard Surface sanitizer and PURE Control food processing aid sold to restaurants, food processors, and distributors. During the nine months ended April 30, 2026, the company generated net product sales of $1.656 million while continuing to operate at a significant loss of $1.873 million, with ongoing challenges related to operating cash burn and liquidity constraints.
Segment Performance
The company operates as a single reportable segment. For the nine months ended April 30, 2026 versus 2025: revenue increased 15% to $1.658 million from $1.438 million; gross profit increased 15% to $957,000 from $835,000; operating losses improved by 18% to $1.580 million from $1.936 million; and net loss improved by 9% to $1.873 million from $2.067 million. PURE Hard Surface revenue grew 25% to $1.550 million, while SILV RION declined 45% to $106,000. For the three months ended April 30, 2026 versus 2025: revenue increased 3% to $506,000 from $491,000; gross profit declined 5% to $269,000 from $283,000; operating losses improved 11% to $518,000 from $584,000; and net loss increased 7% to $624,000 from $580,000.
Key Risk Factors
The company faces substantial doubt regarding its ability to continue as a going concern due to recurring operating losses, negative operating cash flows of $1.324 million for the nine months ended April 30, 2026, and a stockholders deficiency of $5.839 million. Additional risks include significant customer concentration (one customer representing 21% of nine-month product sales), vendor concentration (two vendors accounting for 29% and 13% of purchases), substantial convertible debt obligations of $6.497 million with near-term maturity dates, and dependence on future equity or debt financing which would cause shareholder dilution or impose restrictive covenants.
